Damoctocog Alfa Pegol: A Review in Haemophilia A.

Abstract:

:Damoctocog alfa pegol (Jivi®) is approved in the USA, EU, Japan and Canada for the treatment and prophylaxis of previously treated patients aged ≥ 12 years with haemophilia A. Formulated with a 60 kDa polyethylene glycol (PEG) moiety, damoctocog alfa pegol is an intravenously (IV) administered recombinant factor VIII (rFVIII) product with a longer terminal half-life than non-PEGylated FVIII and rFVIII products. In the multinational phase II/III PROTECT VIII trial, prophylaxis with damoctocog alfa pegol reduced the likelihood of bleeding in previously treated patients aged ≥ 12 years with severe haemophilia A, with dosing schedules ranging from twice weekly to once every 7 days. Interim data from the ongoing extension phase indicated that the reduced annualized bleeding rates (ABRs) were maintained for up to 5.2 years of prophylaxis with damoctocog alfa pegol. Damoctocog alfa pegol was also effective in treating bleeding episodes and in providing haemostatic control during surgery. Damoctocog alfa pegol was generally well tolerated in adult and adolescent patients with severe haemophilia A, with most adverse events considered to be unrelated to treatment. There were no new or confirmed cases of FVIII inhibitor development and anti-PEG antibodies, observed in some patients, were of low titre and transient. Damoctocog alfa pegol extends the available treatment options in previously treated adults and adolescents with haemophilia A, offering the possibility of up to once-weekly administration for suitable patients.

journal_name

Drugs

journal_title

Drugs

authors

Paik J,Deeks ED

doi

10.1007/s40265-019-01152-7

subject

Has Abstract

pub_date

2019-07-01 00:00:00

pages

1147-1156

issue

10

eissn

0012-6667

issn

1179-1950

pii

10.1007/s40265-019-01152-7

journal_volume

79

pub_type

杂志文章,评审

相关文献

DRUGS文献大全
  • Targeting ROS1 Rearrangements in Non-small Cell Lung Cancer: Crizotinib and Newer Generation Tyrosine Kinase Inhibitors.

    abstract::ROS1 gene rearrangements exist in 1-2% of non-small cell lung cancers, typically occurring in younger, never or light smokers with adenocarcinoma. ROS1 gene fusions are potent oncogenic drivers, the presence of which results in the susceptibility of tumours to ROS1-targeted therapy. Crizotinib was the first tyrosine k...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01164-3

    authors: Morris TA,Khoo C,Solomon BJ

    更新日期:2019-08-01 00:00:00

  • Critical appraisal of ramucirumab (IMC-1121B) for cancer treatment: from benchside to clinical use.

    abstract::Although antiangiogenic treatments have produced milestone advances in the treatment of several diseases, and have significantly extended the median survival of cancer patients, these agents share some weaknesses, including a limited impact on the overall cure rate, a fleeting effect because of redundant pathways or e...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-013-0154-8

    authors: Aprile G,Bonotto M,Ongaro E,Pozzo C,Giuliani F

    更新日期:2013-12-01 00:00:00

  • Management of gastroenteritis in early childhood.

    abstract::The most important aspect of modern management of acute diarrhoeal illness in children is that of oral rehydration therapy, and drug therapy is very rarely indicated. Despite the dramatic decline in mortality and morbidity in recent years, there is still the need for continuing education in the appropriate use of oral...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199244010-00005

    authors: Davies A,Jenkins HR

    更新日期:1992-07-01 00:00:00

  • Coronary thrombolysis for evolving myocardial infarction.

    abstract::An acute thrombus at the site of an atherosclerotic obstruction is the usual cause of myocardial infarction. Thrombolytic therapy is an exciting new therapy for reducing the extent of myocardial infarction by lysing intracoronary clots. Such therapy has now been widely applied by: prolonged intravenous infusion of str...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198428050-00004

    authors: Spann JF,Sherry S

    更新日期:1984-11-01 00:00:00

  • Symptomatic Efficacy of Pharmacological Treatments for Knee Osteoarthritis: A Systematic Review and a Network Meta-Analysis with a 6-Month Time Horizon.

    abstract:INTRODUCTION:Several pharmacological treatments aiming at a better symptomatic control of osteoarthritis (OA) are used in daily practice but their efficacy is often disputed. The purpose of this network meta-analysis (NMA) is to assess the efficacy on pain and function of the drugs that are most widely prescribed again...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01423-8

    authors: Beaudart C,Lengelé L,Leclercq V,Geerinck A,Sanchez-Rodriguez D,Bruyère O,Reginster JY

    更新日期:2020-12-01 00:00:00

  • Haemodynamic and antiarrhythmic effects of intravenous flecainide acetate in chronic congestive heart failure.

    abstract::The objective of this study was to evaluate the haemodynamic and antiarrhythmic effects of flecainide acetate in patients with heart failure. Flecainide acetate, a class Ic antiarrhythmic agent, was given intravenously to 9 patients with congestive heart failure and frequent ventricular arrhythmias with nonsustained v...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198500294-00012

    authors: Dunselman PH,Kingma JH,van Wijk LM,Dijk A,Wesseling H,Lie KI

    更新日期:1985-01-01 00:00:00

  • Acamprosate: A Review of Its Use in Alcohol Dependence.

    abstract::Acamprosate (Campral(®), Aotal(®), Regtect(®)) is one of a limited number of pharmacological treatment options approved as an adjunct to psychosocial interventions to facilitate the maintenance of abstinence in alcohol-dependent patients. It has been used in Europe, the USA and other countries for many years and was r...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-015-0423-9

    authors: Plosker GL

    更新日期:2015-07-01 00:00:00

  • [The kidney as a target organ in diabetic patients with arterial hypertension].

    abstract::Diabetes mellitus has become the most common single cause of end-stage renal disease in the Western world. Diabetic nephropathy, as most forms of renal disease leading to end-stage renal failure, is frequently complicated by arterial hypertension. In type 1 diabetes mellitus the reported excess in arterial hypertensio...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:

    authors: Viberti G

    更新日期:2003-01-01 00:00:00

  • Darunavir: a review of its use in the management of HIV infection in adults.

    abstract:UNLABELLED:Darunavir is an oral nonpeptidic HIV-1 protease inhibitor (PI) that is used, together with a low boosting dose of ritonavir, as part of an antiretroviral therapy (ART) regimen in treatment-experienced and -naive patients with HIV-1 infection. Compared with early-generation PIs, boosted darunavir has a high g...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200969040-00007

    authors: McKeage K,Perry CM,Keam SJ

    更新日期:2009-01-01 00:00:00

  • Guillain-Barré syndrome: epidemiology, pathophysiology and management.

    abstract::Guillain-Barré syndrome (GBS) is clinically defined as an acute peripheral neuropathy causing limb weakness that progresses over a time period of days or, at the most, up to 4 weeks. GBS occurs throughout the world with a median annual incidence of 1.3 cases per population of 100 000, with men being more frequently af...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200464060-00003

    authors: Kuwabara S

    更新日期:2004-01-01 00:00:00

  • Treatment of nausea and vomiting in terminally ill cancer patients.

    abstract::Nausea and vomiting is a common and distressing symptom complex in patients with far-advanced cancer, affecting up to 60% of individuals at some stage of their illness. The current approach to the palliative care of patients with nausea and vomiting is based on identifying the cause, understanding its pathophysiology ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/0003495-200868180-00004

    authors: Glare PA,Dunwoodie D,Clark K,Ward A,Yates P,Ryan S,Hardy JR

    更新日期:2008-01-01 00:00:00

  • Zonisamide: a review of its use in the management of adults with partial seizures.

    abstract::Oral zonisamide (Zonegran(®)) is a benzisoxazole derivative chemically unrelated to other antiepileptic agents. It is indicated in the EU as monotherapy in the treatment of partial seizures, with or without secondary generalization, in adults with newly diagnosed epilepsy and as adjunctive therapy to other antiepilept...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-013-0093-4

    authors: Hoy SM

    更新日期:2013-08-01 00:00:00

  • Macitentan: a review of its use in patients with pulmonary arterial hypertension.

    abstract::Macitentan (Opsumit(®)) is an orally active, dual endothelin receptor antagonist (ERA) with tissue targeting properties. Macitentan was approved recently in the EU (as monotherapy or combination therapy) for the long-term treatment of pulmonary arterial hypertension (PAH) in adults of WHO functional class II or III, a...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-014-0266-9

    authors: Dhillon S

    更新日期:2014-09-01 00:00:00

  • Oxatomide. A review of its pharmacodynamic properties and therapeutic efficacy.

    abstract::Oxatomide is an orally active H1-histamine receptor antagonist which, as appears to occur with some other antihistamines, also inhibits mast cell degranulation. Oxatomide has demonstrated response rates similar to those with other more established members of its drug class in a few studies of chronic urticaria and all...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198427030-00003

    authors: Richards DM,Brogden RN,Heel RC,Speight TM,Avery GS

    更新日期:1984-03-01 00:00:00

  • Gemfibrozil. A reappraisal of its pharmacological properties and place in the management of dyslipidaemia.

    abstract::Gemfibrozil improves lipid and apolipoprotein profiles, particularly very low density lipoprotein (VLDL) triglyceride and high density lipoprotein (HDL) cholesterol levels, in patients with dyslipidaemia when administered at a total daily dose of 900 or 1200 mg. As demonstrated by the Helsinki Heart Study, these effec...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199651060-00009

    authors: Spencer CM,Barradell LB

    更新日期:1996-06-01 00:00:00

  • Long term management of oesophageal varices.

    abstract::Effective control of variceal rebleeding (secondary prophylaxis) or prevention of the initial bleeding (primary prophylaxis) are the main objectives of the treatment of portal hypertension. Endoscopic sclerotherapy is the treatment of choice for secondary prophylaxis, since it significantly decreases rebleeding and, t...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199200442-00007

    authors: Sarin SK

    更新日期:1992-01-01 00:00:00

  • Ondansetron. An update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting.

    abstract::Ondansetron is a selective 5-HT3 receptor antagonist which has previously been reported in the Journal to be a promising new agent for use as prophylaxis against nausea and vomiting caused by chemotherapy and radiotherapy. Since the publication of this original review, further studies have been published that show ond...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199345060-00006

    authors: Markham A,Sorkin EM

    更新日期:1993-06-01 00:00:00

  • Management of cystitis in young women.

    abstract::The common clinical problem of recurrent symptomatic urinary tract infections (UTI) in young women may be inconvenient and distressing to both the patient and her family, particularly if the infections are not managed in a rational manner. A suggested approach is included in table 1. ...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-197713020-00003

    authors: Bailey RR

    更新日期:1977-02-01 00:00:00

  • Advanced-stage follicular lymphoma in the rituximab era: when should patients receive anthracycline-based chemotherapy?

    abstract::Follicular lymphoma (FL), the most common subtype of indolent lymphoma, is usually diagnosed at an advanced stage (III-IV), although patients are often asymptomatic. Traditionally, a palliative approach to management has been taken, cycling through watchful waiting, radiotherapy, oral alkylating agents and, eventually...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/11317050-000000000-00000

    authors: Pettengell R

    更新日期:2009-01-01 00:00:00

  • Mammalian cell-derived somatropin : a review of its use in the management of HIV-associated wasting.

    abstract::HIV-associated wasting, characterised by progressive loss of lean body mass and bodyweight, remains a significant problem in the era of highly active antiretroviral therapy (HAART). Loss of body cell mass, a component of lean body mass, is associated with decreased survival. Somatropin (recombinant human growth hormon...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200666030-00014

    authors: Goldsmith DR,Wagstaff AJ

    更新日期:2006-01-01 00:00:00

  • Correction to: Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.

    abstract::The article Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection, written by Emma D. Deeks, was originally published Online First without open access. After publication in volume 78, issue 17, pages 1817-1828 Gilead Sciences requested that the article be Open Choice to make the article an open ...

    journal_title:Drugs

    pub_type: 杂志文章,已发布勘误

    doi:10.1007/s40265-019-01101-4

    authors: Deeks ED

    更新日期:2019-04-01 00:00:00

  • The role of arachidonic acid metabolites in gastrointestinal homeostasis. Biochemical, histological and clinical gastrointestinal effects.

    abstract::Metabolites of arachidonic acid have a broad range of physiological functions in the gastrointestinal tract, and seem to be involved in certain disturbances of gastrointestinal integrity and function. Prostaglandins inhibit gastric acid secretion, apparently via an adenylate cyclase-linked receptor, and also stimulate...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198700331-00007

    authors: Isselbacher KJ

    更新日期:1987-01-01 00:00:00

  • Supra-oesophageal manifestations of gastro-oesophageal reflux disease.

    abstract::The extra-oesophageal signs that are most commonly related to gastro-oesophageal reflux include chest pain, asthma, chronic cough, posterior laryngitis and dental erosions. It is characteristic to find in such patients a poor presence of symptoms and endoscopic and pH-metric findings that are common in typical reflux....

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200565001-00010

    authors: Rodríguez-Téllez M

    更新日期:2005-01-01 00:00:00

  • Panic disorder. Pathophysiology and drug treatment.

    abstract::Advances over the past 2 decades in our understanding of the biology of panic disorder have paralleled a remarkable increase in the development of new pharmacological agents with antipanic effects. Although we can not presently use biological tests to help with our choice of therapeutic agent for individual patients, ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199549030-00002

    authors: Johnson MR,Lydiard RB,Ballenger JC

    更新日期:1995-03-01 00:00:00

  • Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C.

    abstract::Pegylation of interferon-alpha-2a is associated with improved sustained virological response rates in patients with chronic hepatitis C. Subsequently, combination therapy with peginterferon-alpha-2a (40kD) [Pegasys] and ribavirin (Copegus trade mark, Rebetol) was investigated to establish if the efficacy of peginterfe...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200363070-00008

    authors: Keating GM,Curran MP

    更新日期:2003-01-01 00:00:00

  • Pharmacokinetics of ofloxacin in patients on haemodialysis treatment.

    abstract::Serum concentrations and pharmacokinetic parameters of ofloxacin were measured in 10 patients on haemodialysis treatment. Serum half-life during the interdialytic interval was 48 hours, and during haemodialysis treatment 10 hours. The decrease in serum concentrations during a 4-hour haemodialysis was 25%. After severa...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198700341-00014

    authors: Dörfler A,Schulz W,Burkhardt F,Zichner M

    更新日期:1987-01-01 00:00:00

  • Oral etoposide in lymphoma.

    abstract::Etoposide is one of the most active agents for the therapy of lymphomas. Oral etoposide has proven to be active in and clearly beneficial for patients with previously treated lymphomas. The optimal dose and schedule of oral etoposide for use in combination chemotherapy are still uncertain, but low daily doses (50 to 1...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199958003-00006

    authors: Greco FA

    更新日期:1999-01-01 00:00:00

  • Correction to: Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension.

    abstract::The article Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension, written by Sheridan Hoy, was originally published Online First without open access. ...

    journal_title:Drugs

    pub_type: 杂志文章,已发布勘误

    doi:10.1007/s40265-018-0925-3

    authors: Hoy SM

    更新日期:2018-06-01 00:00:00

  • Crizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer.

    abstract::Crizotinib (Xalkori(®)) is an orally active, small molecule inhibitor of multiple receptor tyrosine kinases, including anaplastic lymphoma kinase (ALK), c-Met/hepatocyte growth factor receptor and c-ros oncogene 1. In the EU, crizotinib has been conditionally approved for the treatment of adults with previously treate...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-013-0142-z

    authors: Frampton JE

    更新日期:2013-12-01 00:00:00

  • Transdermal clonidine. A preliminary review of its pharmacodynamic properties and therapeutic efficacy.

    abstract::The clonidine transdermal therapeutic system (TTS) is a cutaneous delivery device which provides therapeutically effective doses of clonidine at a constant rate over 7 days. In clinical trials it reduces blood pressure in patients with mild to moderate hypertension as effectively as oral clonidine but with greater sta...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198835020-00003

    authors: Langley MS,Heel RC

    更新日期:1988-02-01 00:00:00